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Abstract
Molecular Cancer is as a forum for cutting edge cancer-related papers. This editorial will answer
frequently asked question about this open-access and on-line journal as well as its publisher BioMed
Central.
Editorial
There is no question that immediate and unrestricted ac-
cess to information stimulates scientific communication.
The Freedom of Information Act "provides individuals
with a right to access to records in the possession of the
federal government" http://www.nih.gov/icd/od/foia/.
Indeed, almost every research funding comes from indi-
viduals and/or governmental institutions, and I firmly be-
lieve it is the right of everyone to access any kind of
scientific information without barriers and free of charge.
There is no limitation to positive data, because many
"prominent medical journals often provide insufficient
information to assess the validity of studies with negative
results" [1] to allow a rigorous evaluation of the quality of
these results. A newly launched journal focuses on "well
documented results/conclusions that are unexpected,
controversial, provocative and/or negative in the context
of current tenets" [2]. Molecular Cancer and its publisher
BioMed Central are fully devoted to open access publish-
ing and there is no doubt that this will be the golden
standard for scientific publishing [3–10].
Molecular Cancer is embedded in a family of related on-
line journals, all with BioMed Central's open-access poli-
cy. Molecular Cancer focuses on all areas of cancer-related
science, from bench and bedside [11] and publishes im-
mediately after accepting; this concept is paying us back
[12–19]. We, the editors of Molecular Cancer, are willing
to make the journal even more attractive and are not
afraid of work and effort. We do not charge extra for color-
ed pictures, amount of data presented in the paper and/or
supplemental data and so on.
Everything produces costs [8]; who will pay for it [20,21]?
BioMed Central charges a flat fee of $500 after a paper is
being accepted for publication. In return, the authors re-
tain their copyright and the paper is freely accessible with-
out barriers and fees to everyone. Again, visibility and
access rates are higher. There are no costs for an unlimited
number of papers if the submitting author's Institution is
a member of BioMed Central http://www.biomedcen-
tral.com/inst/. Next, a number of funding agencies explic-
itly allow direct use of their grants to covering the article
processing charges:
• Canadian Institutes of Health Research http://www.cihr-
irsc.gc.ca/
• Deutsche Forschungsgemeinschaft http://www.dfg.de/
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scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
• Fonds zur Förderung der wissenschaftlichen Forschung
http://www.fwf.ac.at/
• Health Research Board http://www.hrb.ie/
• Howard Hughes Medical Institute http://www.hh-
mi.org/
• International Human Frontier Science Program Organi-
zation http://www.hfsp.org/
• Israel Science Foundation http://www.isf.org.il/
• National Health Service http://www.doh.gov.uk/
• National Institutes of Health http://www.nih.gov/
• National Science Foundation http://www.nsf.gov/
• Rockefeller Foundation http://www.rockfound.org/
• Swiss National Science Foundation http://www.snf.ch/
There is further assistance in publication costs. The Soros
Foundation http://www.soros.org/ allows authors from
certain countries to apply for help in getting manuscripts
published.
Conclusion
Molecular Cancer is an open-access and on-line journal;
its publisher fulfills the Freedom of Information Act and
guarantees access to papers without barriers and fees. Mo-
lecular Cancer does not charge for colored pictures,
amount of data presented in the paper and/or supplemen-
tal data, page charges etc. BioMed Central charges a flat fee
of $500 after a paper is being accepted for publication; in
return, the authors retain their copyright. A number of
funding agencies explicitly allow direct use of their grants
to cover article processing charges; there are no costs for
an unlimited number of accepted papers if the submit-
ting author's Institution is a member of BioMed Central.
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